![Page Image](https://mumcdnstorage.blob.core.windows.net/dwnews/2023/09/Heme_Today_Square_Logo_500x500.png)
Hemophilia
Quality of life improvement is among the benefits from this agent in patients with congenital disease.
A retrospective observational study's clearest takeaway was that the agent can reduce spontaneous bleeding in severe disease.
These proof-of-concept data may spur further studies toward developing a single-intervention cure for patients.
Patients with hemophilia A who received prophylaxis had a reduced risk for ICH.
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Advertisement
Expert Interviews on Hematology
Advertisement